Veldman Alex, Fischer Doris, Voigt Burkhard, Beyer Peter A, Schlösser Rolf, Allendorf Antje, Kreuz Wolfhardt
Department of Pediatrics, Division of Neonatalogy, J W Goethe University Hospital, Theodor Stern Kai 7, 60590 Frankfurt/Main, Germany.
Intensive Care Med. 2002 Nov;28(11):1635-7. doi: 10.1007/s00134-002-1489-x. Epub 2002 Sep 11.
Massive hemorrhage with shock is a common problem for the intensivist. The use of recombinant activated factor VII (rFVIIa), known as efficient treatment for hemophilia, has been reported to control severe bleeding episodes in critically care patients, but never in preterm neonates.
Case report (two cases) and review of the literature.
Neonatal intensive care unit, university teaching hospital.
Two preterm neonates with life-threatening hemorrhages, from the liver and spleen in one patient and from the lung in the other.
Intravenous administration of 150/200 microg/kg of rFVIIa (Novoseven, NovoNordisk, Copenhagen, Denmark).
Complete hemostasis 10 min after the second bolus in the two patients.
For the intensivist, the successful use of rFVIIa in these patients and others lacking pre-existing coagulopathies points to rFVIIa as a novel therapeutic approach for patients presenting with massive life-threatening hemorrhage.
大出血伴休克是重症监护医生面临的常见问题。重组活化凝血因子VII（rFVIIa）作为治疗血友病的有效药物，已被报道可控制危重症患者的严重出血事件，但从未用于早产新生儿。
病例报告（两例）及文献综述。
大学教学医院的新生儿重症监护病房。
两名有危及生命出血情况的早产新生儿，一例出血来自肝脏和脾脏，另一例来自肺部。
静脉注射150/200微克/千克的rFVIIa（诺其，丹麦诺和诺德公司，哥本哈根）。
两名患者在第二次推注后10分钟完全止血。
对于重症监护医生而言，rFVIIa在这些患者以及其他无既往凝血功能障碍患者中的成功应用表明，rFVIIa是治疗出现危及生命大出血患者的一种新的治疗方法。
